<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957954</url>
  </required_header>
  <id_info>
    <org_study_id>V001</org_study_id>
    <secondary_id>R01EY021797</secondary_id>
    <nct_id>NCT03957954</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy for Limbal Stem Cell Deficiency</brief_title>
  <official_title>Safety and Feasibility of Cultivated Autologous Limbal Stem Cells (cLSC) for Limbal Stem Cell Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I study will collect preliminary information on the activity and safety of cLSC.&#xD;
      We will investigate the ability to manufacture and transplant cLSC onto the cornea&#xD;
      successfully at the time of surgery (feasibility), and have cLSC begin to populate the ocular&#xD;
      surface (efficacy) without serious adverse events (safety).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 patients with severe to total Limbal Stem Cell Deficiency (LSCD) in one eye attributable&#xD;
      to injury or ocular surgery. The first 5 eyes will receive the cLSCs to determine the&#xD;
      feasibility and safety. Then the subsequent 15 eyes will be randomized into cLSC group and a&#xD;
      scleral lens treatment (SCL) control group in a 2:1 ratio in blocks of 3 or 6 using a random&#xD;
      number generator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of cLSC Transplant pertaining to Infection and/or Corneal Perforation</measure>
    <time_frame>12 months for all participants</time_frame>
    <description>Safety assessed by incidence of Serious Adverse Events (SAEs) directly related to cLSC: infection and/or corneal perforation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of cLSC Transplant pertaining to Manufacturing meeting Release Criteria</measure>
    <time_frame>12 months for all participants</time_frame>
    <description>Feasibility assessed by successful manufacturing of cLSC from biopsy that meets release criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of cLSC Transplant pertaining to Manufacturing without Contamination</measure>
    <time_frame>12 months for all participants</time_frame>
    <description>Feasibility assessed by successful cLSC manufacturing without contamination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the Area of Corneal Epithelial Defect</measure>
    <time_frame>At 6 months and 12 months in both cLSC and the control groups</time_frame>
    <description>Evaluate changes in the area of corneal epithelial defect (ED) or lack of ED.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Clinical Score</measure>
    <time_frame>At 6 months and 12 months in both cLSC and the control groups</time_frame>
    <description>Evaluate changes in the clinical score determined by slit lamp examination using fluorescein staining and confocal imaging.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Limbal Stem-cell Deficiency</condition>
  <arm_group>
    <arm_group_label>Cultivated Limbal Stem-Cells (cLSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of cultivated limbal stem-cells (cLSC), size between 7.6 to 15 mm in the average diameter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scleral Contact Lens Device (SCL)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scleral contact lens device (SCL) will be fitted to stabilize and improve ocular surface.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cLSC</intervention_name>
    <description>Transplantation of cLSC</description>
    <arm_group_label>Cultivated Limbal Stem-Cells (cLSC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scleral contact lens (SCL)</intervention_name>
    <description>Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.</description>
    <arm_group_label>Scleral Contact Lens Device (SCL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥18 years of age.&#xD;
&#xD;
          2. Best corrected visual acuity in the affected eye of 20/200 or less.&#xD;
&#xD;
          3. Documentation of a LSCD diagnosis and the central cornea is affected.&#xD;
&#xD;
          4. Absence of lagophthalmos and eyelid abnormality&#xD;
&#xD;
          5. Adequate forniceal depth is ≥ 5 mm.&#xD;
&#xD;
          6. LSCD fails to resolve by surgical treatments of the ocular surface during the previous&#xD;
             6 months of screening visit.&#xD;
&#xD;
          7. If the etiology of LSCD is due to chemical injury, a minimal interval of 1 year since&#xD;
             the initial chemical injury is required.&#xD;
&#xD;
          8. A Schirmer test result at 5 minute of ≥5 mm of wetting.&#xD;
&#xD;
          9. Absence of active infectious keratitis in either eye at the Enrollment Visit.&#xD;
&#xD;
         10. Have a life expectancy ≥ 2 years after enrollment.&#xD;
&#xD;
        Main exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, breastfeeding, or unwilling to practice birth control during participation&#xD;
             in the study.&#xD;
&#xD;
          2. Presence of a condition or abnormality that in the opinion of the Investigator would&#xD;
             compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          3. Exposure keratopathy or lagophthalmos of the study eye.&#xD;
&#xD;
          4. Persistent severe ocular surface inflammation and/or meibomian gland dysfunction&#xD;
&#xD;
          5. Chemical injury occurred less than 12 months ago.&#xD;
&#xD;
          6. Presence of ocular surface tumor.&#xD;
&#xD;
          7. Uncontrolled diabetes with last hemoglobin A1C (HgA1C) &gt;8.5.&#xD;
&#xD;
          8. Presence of known allergies to any of the cLSC components.&#xD;
&#xD;
          9. Current participation in another simultaneous medical investigation or trial.&#xD;
&#xD;
         10. Unable to be compliant with or complete the requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Deng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stein Eye Institute UCLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clemence Bonnet, MD</last_name>
    <phone>310-794-7813</phone>
    <email>CBonnet@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sofia Gudiel</last_name>
    <email>SGudiel@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemence Bonnet, MD</last_name>
      <phone>310-794-7813</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Sophie Deng, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

